Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 5 von Hippel-Lindau Disease 2 Pheochromocytoma 2 Paraganglioma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Kidney Neoplasms 1 Hemangioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 11 Cisplatin 11 Specimen Handling 8 Magnetic Resonance Spectroscopy 8 durvalumab 4 Platinum 4 Pemetrexed 4 Paclitaxel 4 Cyclophosphamide 4 1,2-diaminocyclohexaneplatinum II citrate 4 fludarabine 3 cemiplimab 3 Radiotherapy, Intensity-Modulated 3 Radiotherapy 3 Oxaliplatin 3 Nivolumab 3 Fluorouracil 3 Carboplatin 3 Biopsy 3 poly ICLC 2 osimertinib 2 cabozantinib 2 atezolizumab 2 Heavy Ion Radiotherapy 2 Gemcitabine 2 Drug Therapy 2 Docetaxel 2 Cetuximab 2 Capecitabine 2 zipalertinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07227402 2026-03-16

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡